Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Functional Inhibition of Mesenchymal Stem and Progenitor Cells (MSPC) Significantly Contributes to Hematopoietic Insufficiency with Acute Myeloid Leukemia (AML)

Stefanie Geyh, Manuel Rodríguez-Paredes, Cyrus Khandanpour, MD, Ron-Patrick Cadeddu, Paul Jäger, Christoph Zilkens, Ulrich Dührsen, MD, C. Matthias Wilk, Roland Fenk, MD, Norbert Gattermann, MD PhD, Ulrich Germing, Guido Kobbe, MD, Frank Lyko, PhD, Rainer Haas, MD, Thomas Schroeder, MD

Blood (2014) 124 (21): 3492.

https://doi.org/10.1182/blood.V124.21.3492.3492

Published: 2014

Journal Articles

Diagnosis and Treatment of Myeloproliferative Neoplasms in Germany: First Results from the SAL-MPN Registry

Andrea Kaifie, MD, Susanne Isfort, MD, Dominik Wolf, MD, Mathias Hanel, MD, Christoph Maintz, MD, Norbert Gattermann, MD PhD, Uwe Platzbecker, MD, Eray Goekkurt, MD, Ina Boeters, MD, Richard Hansen, MD, Fabian Lang, MD, Joachim R. Goethert, Karla Bennemann, MD, Christoph Rollig, MD MSC, Hubert Serve, MD, Wolfgang E Berdel, MD, Gerhard Ehninger, MD, Tim H Bruemmendorf, MD, Steffen Koschmieder, MD

Blood (2014) 124 (21): 5561.

https://doi.org/10.1182/blood.V124.21.5561.5561

Published: 2014

Journal Articles

Monitoring of Wilms’ Tumor 1 (WT1) Expression in Peripheral Blood (PB) of Patients with Myelodysplastic Syndromes (MDS) By a Standardized European Leukemia Net (ELN)-Certified Assay to Detect Minimal Residual Disease (MRD) and Guide Therapeutic Interventions Following Allogeneic Transplantation

Thomas Schroeder, MD, Sabrina Pechtel, Marius Lamers, Ariane Dienst, Esther Schuler, Elena Rachlis, MD, Nadija Wegener, Andrea Kündgen, Mustafa Kondakci, MD, Roland Fenk, MD, Norbert Gattermann, MD PhD, Rainer Haas, MD, Ulrich Germing, Guido Kobbe, MD

Blood (2014) 124 (21): 4661.

https://doi.org/10.1182/blood.V124.21.4661.4661

Published: 2014

Journal Articles

Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)

Blood (2014) 124 (21): 409.

https://doi.org/10.1182/blood.V124.21.409.409

Published: 2014

Journal Articles

Results of a Multicenter Treatment Survey Yielding Insights Into Diagnosis and Management of MDS Patients In Daily Clinical Practice In Germany

Norbert Gattermann, MD, PhD, Andrea Kuendgen, MD, Lenka Kellermann, BS, MBA, Matti Zeffel, BS, Hans-Juergen Berger, PhD, Ulrich Germing, MD

Blood (2010) 116 (21): 4959.

https://doi.org/10.1182/blood.V116.21.4959.4959

Published: 2010

Journal Articles

Differences In Clinical Characteristics and Prognostic Features Between Patients with Myelodysplastic Syndromes (MDS) From Korea, Japan, and Germany

Andrea Kuendgen, Je-Hwan Lee, Akira Matsuda, Kyoo Hyung Lee, Jung-Hee Lee, Norbert Gattermann, MD, PhD, Rainer Haas, Ulrich Germing

Blood (2010) 116 (21): 1882.

https://doi.org/10.1182/blood.V116.21.1882.1882

Published: 2010

Journal Articles

Outcome of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-T) In a Large Cohort of Patients

Blood (2010) 116 (21): 4113.

https://doi.org/10.1182/blood.V116.21.4113.4113

Published: 2010

Journal Articles

Safety of Deferasirox (Exjade®) in Myelodysplastic Syndromes (MDS) and Non-MDS Patients with Transfusional Iron Overload: A Pooled Analysis Focusing On Renal Function.

Mathias Schmid, M. Domenica Cappellini, John B. Porter, Peter L. Greenberg, MD, Tomasz Lawniczek, Sabine Glaser, Victor Dong, Norbert Gattermann, MD, PhD

Blood (2009) 114 (22): 1768.

https://doi.org/10.1182/blood.V114.22.1768.1768

Published: 2009

Journal Articles

Incidence and Prevalence of Patients with Myelodysplastic Syndromes (MDS) in Düsseldorf 1996-2005.

Judith Neukirchen, W. Marieke Schoonen, Carlo Aul, Rainer Haas, Norbert Gattermann, MD, PhD, Ulrich Germing

Blood (2009) 114 (22): 1774.

https://doi.org/10.1182/blood.V114.22.1774.1774

Published: 2009

Journal Articles

Matched-Pair Analysis of 186 MDS Patients Receiving Iron Chelation Therapy or Transfusion Therapy Only.

Frank Fox, Andrea Kündgen, Kathrin Nachtkamp, Corinna Strupp, Rainer Haas, Ulrich Germing, Norbert Gattermann, MD, PhD

Blood (2009) 114 (22): 1747.

https://doi.org/10.1182/blood.V114.22.1747.1747

Published: 2009

Journal Articles

Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data.

Hagop M. Kantarjian, MD, Elias Jabbour, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Kapil N. Bhalla, MD, Javier Pinilla-Ibarz, MD, PhD, Richard A. Larson, MD, Norbert Gattermann, MD, PhD, Oliver G. Ottmann, MD, Jim Wang, PhD, Richard C. Woodman, MD, Michele Baccarani, MD, Philipp D. le Coutre, MD, Jorge Cortes, MD

Blood (2009) 114 (22): 3298.

https://doi.org/10.1182/blood.V114.22.3298.3298

Published: 2009

Journal Articles

Influence of Different Treatment Modalities On the Prognosis of Patients with High Risk MDS Aged Above 60 Years. A Matched-Pairs Analysis.

Kathrin Nachtkamp, Norbert Gattermann, MD, PhD, Julia Adler, Rainer Haas, Ulrich Germing, Andrea Kuendgen

Blood (2009) 114 (22): 2769.

https://doi.org/10.1182/blood.V114.22.2769.2769

Published: 2009

Journal Articles

Deferasirox (Exjade®) Is Effective and Well Tolerated in Chelation-Naive and Previously Chelated Patients with Transfusion-Dependent Myelodysplastic Syndromes (MDS).

Mathias Schmid, Agnès Guerci-Bresler, Matteo Della Porta, Kerry Taylor, Dany Habr, Gabor Domokos, Bernard Roubert, Christian Rose, Norbert Gattermann, MD, PhD

Blood (2009) 114 (22): 3806.

https://doi.org/10.1182/blood.V114.22.3806.3806

Published: 2009

Journal Articles

Deep Sequencing the Tet2 Gene in 360 Patients with Myeloid Neoplasms Provides a Comprehensive and Quantitative Mutation Map and Reveals Low Level Mutant Clones.

Alexander E Smith, Azim M Mohamedali, PhD, Syed a Mian, Technician, Nicholas C Lea, BSc, PhD, Nigel Westwood, PhD, CSci, FIBMS, Austin G Kulasekararaj, Joop Gaken, PhD, Corinna Strupp, Norbert Gattermann, MD, PhD, Ulrich Germing, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2009) 114 (22): 733.

https://doi.org/10.1182/blood.V114.22.733.733

Published: 2009

Journal Articles

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

Hagop M. Kantarjian, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Kapil N. Bhalla, MD, Javier Pinilla-Ibarz, MD, PhD, Richard A. Larson, MD, Norbert Gattermann, MD, PhD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD, Jerald P. Radich, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD, MBBS, Giovanni Martinelli, MD, Dong-Wook Kim, MD, PhD, Yaping Shou, MD, PhD, Neil J. Gallagher, MD, PhD, Jim Wang, PhD, Jorge Cortes-Franco, MD, Michele Baccarani, MD, Philipp D. le Coutre, MD

Blood (2009) 114 (22): 1129.

https://doi.org/10.1182/blood.V114.22.1129.1129

Published: 2009

Journal Articles

Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP).

Jorge Cortes, MD, Elias Jabbour, MD, Andreas Hochhaus, MD, Philipp le Coutre, MD, Michele Baccarani, MD, Kapil N. Bhalla, MD, Gert Ossenkoppele, MD, PhD, Norbert Gattermann, MD, PhD, Ariful Haque, Neil Gallagher, Francis Giles, MD, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 1040.

https://doi.org/10.1182/blood.V110.11.1040.1040

Published: 2007

Journal Articles

Transcriptional Changes Induced by Imatinib and Nilotinib in the Chronic Myelogenous Leukemia (CML) Cell Line K562.

Frank Neumann, MD, Daniela C. Bruennert, Anne-Marie Koch, Ingmar Bruns, MD, Norbert Gattermann, MD, PhD, Ralf Kronenwett, MD, PhD, Rainer Haas, MD, PhD

Blood (2007) 110 (11): 4540.

https://doi.org/10.1182/blood.V110.11.4540.4540

Published: 2007

Journal Articles

Nilotinib Is Safe and Effective in Accelerated Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib Resistance or Intolerance.

Philipp le Coutre, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Jane Apperley, MD, Oliver G. Ottmann, MD, Norbert Gattermann, MD, PhD, Stephen G. O’Brien, MD, PhD, Kazimierz Kuliczkowski, Richard A. Larson, MD, Dong-Wook Kim, MD, PhD, Ariful Haque, Neil Gallagher, Michele Baccarani, MD, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 471.

https://doi.org/10.1182/blood.V110.11.471.471

Published: 2007

Journal Articles

Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance.

Hagop M. Kantarjian, MD, Andreas Hochhaus, MD, Jorge Cortes, MD, Giovanni Martinelli, MD, Kapil N. Bhalla, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Gert Ossenkoppele, MD, PhD, Norbert Gattermann, MD, PhD, Ariful Haque, Neil Gallagher, Michele Baccarani, MD, Philipp le Coutre, MD

Blood (2007) 110 (11): 735.

https://doi.org/10.1182/blood.V110.11.735.735

Published: 2007

Journal Articles

Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS.

Detlef Haase, MD, PhD, Ulrich Germing, MD, PhD, Julie Schanz, MD, Michael Pfeilstoecker, MD, PhD, Barbara Hildebrandt, PhD, Michael Luebbert, MD, PhD, Aristoteles Giagounidis, MD, Carlo Aul, MD, PhD, Lorenz Truemper, MD, PhD, Thomas Mueller, PhD, Peter Valent, MD, PhD, Norbert Gattermann, MD, PhD, Christa Fonatsch, PhD, Otto Krieger, MD, PhD, Reinhard Stauder, MD, Christian Steidl, MD

Blood (2006) 108 (11): 252.

https://doi.org/10.1182/blood.V108.11.252.252

Published: 2006

NARROW

Functional Inhibition of Mesenchymal Stem and Progenitor Cells (MSPC) Significantly Contributes to Hematopoietic Insufficiency with Acute Myeloid Leukemia (AML)

Diagnosis and Treatment of Myeloproliferative Neoplasms in Germany: First Results from the SAL-MPN Registry

Monitoring of Wilms’ Tumor 1 (WT1) Expression in Peripheral Blood (PB) of Patients with Myelodysplastic Syndromes (MDS) By a Standardized European Leukemia Net (ELN)-Certified Assay to Detect Minimal Residual Disease (MRD) and Guide Therapeutic Interventions Following Allogeneic Transplantation

Results of a Multicenter Treatment Survey Yielding Insights Into Diagnosis and Management of MDS Patients In Daily Clinical Practice In Germany

Differences In Clinical Characteristics and Prognostic Features Between Patients with Myelodysplastic Syndromes (MDS) From Korea, Japan, and Germany

Outcome of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-T) In a Large Cohort of Patients

Safety of Deferasirox (Exjade®) in Myelodysplastic Syndromes (MDS) and Non-MDS Patients with Transfusional Iron Overload: A Pooled Analysis Focusing On Renal Function.

Incidence and Prevalence of Patients with Myelodysplastic Syndromes (MDS) in Düsseldorf 1996-2005.

Matched-Pair Analysis of 186 MDS Patients Receiving Iron Chelation Therapy or Transfusion Therapy Only.

Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data.

Influence of Different Treatment Modalities On the Prognosis of Patients with High Risk MDS Aged Above 60 Years. A Matched-Pairs Analysis.

Deferasirox (Exjade®) Is Effective and Well Tolerated in Chelation-Naive and Previously Chelated Patients with Transfusion-Dependent Myelodysplastic Syndromes (MDS).

Deep Sequencing the Tet2 Gene in 360 Patients with Myeloid Neoplasms Provides a Comprehensive and Quantitative Mutation Map and Reveals Low Level Mutant Clones.

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP).

Transcriptional Changes Induced by Imatinib and Nilotinib in the Chronic Myelogenous Leukemia (CML) Cell Line K562.

Nilotinib Is Safe and Effective in Accelerated Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib Resistance or Intolerance.

Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance.

Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only